Autopsy report · NCT04308395
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
Cause of deathOther
“Study was terminated early due to low blinded event rate and this study termination is not related to safety of the drug Patidegib Topical Gel, 2%.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 1 year 1 month before it stopped.
- 108 participants enrolled.
- Results were posted on the registry 3 years 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Sol-Gel Technologies, Ltd.
- Sponsor type
- Industry
- Conditions
- Basal Cell Nevus Syndrome
- Interventions
- Patidegib Topical Gel, 2%
- Participants
- 108
- Sites
- 37
- Countries
- Belgium, Denmark, France, Germany, Italy, Netherlands, Spain, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.